SUMMARY Of 84 men with non-gonococcal urethritis (NGU), 24 yielded Chlamydia trachomatis by either cell culture or MicroTrak immunofluorescence test. All 84 were treated with bacampicillin 800 mg twice a day for seven days. Five (one chlamydia positive) defaulted from follow up 10 to 14 days after the start of treatment. Of the 23 chlamydia positive patients who attended follow up, 22 became chlamydia negative; 14 ofthe 23 patients also became asymptomatic and had normal urethral smears. Of the 56 chlamydia negative patients who attended follow up, 21 were cleared of their urethritis.
Chlamydial infections are becoming increasingly common in many parts of the world. In fact, they are the most rapidly increasing sexually transmitted disease (STD) apart from the acquired immune deficiency syndrome (AIDS).' Chlamydiae are not only a major cause of genital infections in both men and women, but also cause serious complications, especially in women, which often lead to infertility. In men, Chlamydia trachomatis is the organism most often isolated from patients with non-gonococcal urethritis (NGU).2 Tetracyclines are generally used as the first line antimicrobial agents to treat chlamydial infections, and erythromycin base or stearate are alternatives for patients in whom tetracyclines are contraindicated or not tolerated. Ampicillins have moderate activity against C trachomatis; the minimum inhibitory concentrations of ampicillin, pivampicillin, and amoxycillin being 0.25, 0.25, and 2 mg/l respectively.34 Amoxycillin 750 mg given orally three times a day for 10 days has apparently eliminated chlamydiae from six men with NGU followed up for 24 to 48 days.5 Pivampicillin 1.5 to 3 g a day orally for 10 days has been found to be highly effective in eradicating C trachomatis from the lower genital tracts of men and women.3
Bacampicillin hydrochloride is an ester prodrug of ampicillin. It is almost completely (98%) absorbed after being taken by mouth and is rapidly hydrolysed in the blood to its active metabolite, ampicillin.67
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Specimens for MicroTrak direct immunofluorescence studies were rolled in a 6 mm well Teflon coated glass microscope slide, fixed with acetone, and air dried. The fixed slide was subsequently stained with monoclonal antibody specific to chlamydiae, which was conjugated with fluorescein isothiocyanate (FITC). The stained smear was examined using an Olympus Venox fluorescence microscope with excitation filter BG-12 and a x 40 objective. The smear was considered to be positive when 10 or more elementary bodies staining bright apple green were observed against a background of cellular materials.
The patients were chlamydia positive or chlamydia negative according to the results of the chlamydial tests before treatment. In the chlamydia positive patients, clinical cure was defined by the absence of symptoms and signs and by normal urethral smears, 
Results
Of 84 patients (mean age 28 (range 18-45)) who participated in the study, five (one chlamydia positive) defaulted from follow up, leaving 79 patients for the evaluation of response. At the first visit, cultures for N gonorrhoeae were all negative in the 84 patients included in the study. Table 1 shows the results of the chlamydial tests before treatment, chlamydiae being identified in 24 of the 84 patients by cell culture or MicroTrak, or both. Table 2 shows the results of treatment. Nine of the 23 chlamydia positive patients who attended follow up still had symptoms or signs, or both, of urethritis, although their chlamydial test results were negative after treatment.
Two patients reported side effects after non-leading questions; one was drowsiness and one was mild diffuse alopecia. These two side effects were considered unlikely to be related to the treatment.
Discussion
The results of the study reported here showed that bacampicillin hydrochloride 800 mg twice a day for seven days was effective against chlamydial urethritis in men. The high cure rate of 96% (22/23) in the The pattem of adverse drug reactions to bacampicillin follows that of other aminopenicillins, with a predominance of dermatological reactions and gastrointestinal symptoms. The incidence ofreports of side effects, however, was at least half that for oral ampicillin. The side effects to bacampicillin given in dosages varying from 400 mg twice a day to 800 mg three times a day for 10 days to 5316 patients included skin manifestations (2%), upper gastrointestinal symptoms (3%), and lower gastrointestinal symptoms (2%) (Pichler H, unpublished observation). The two side effects (drowsiness and diffuse loss of hair) noted in our study were probably not related to the intake of bacampicillin.
Concomitant gonococcal and chlamydial infections are common in many parts of the world. C trachomatis has been recovered from 27-63% of women with endocervical gonorrhoea and from 4-33% of men with urethral gonorrhoea.9 In Singapore, C trachomatis has been isolated from 26% (35/136) of men with gonococcal urethritis.'3 Bacampicillin 1600 mg given with probenecid 1 g has been found to be highly effective (more than 95%) against infections with non-J-lactamase producing gonococci." In geographical areas with a low prevalence of infection with fi lactamase producing gonococci, therefore, concomitant gonococcal and chlamydial infection may be treated with bacampicillin hydrochloride 1-6 g and probenecid 1 g followed by bacampicillin 800 mg twice daily for seven days. In areas with a high prevalence of infection with P lactamase producing gonococci, however, the use of bacampicillin is not advisable, as it is not effective against P lactamase producing gonococci.
In conclusion, 29% (24/84) of the men with NGU who we studied in Singapore were infected with C trachomatis. Bacampicillin 800 mg twice a day for seven days seems to be efficacious against chlamydial urethritis in men. It may be particularly useful in patients who are allergic to or intolerant of both tetracycline and erythromycin. It may also be a useful Lee, Lim, 
